CLINICAL STUDIES
Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes
Hisashi Kai, MD, PhDa,
Hisao Ikeda, MD, PhDa,
Hideo Yasukawa, MD, PhDa,
Mamiko Kai, PhD*,
Yukihiko Seki, MDa,
Fumitaka Kuwahara, MDa,
Takafumi Ueno, MD, PhDa,
Kenzo Sugi, MD, PhD and
Tsutomu Imaizumi, MD, PhD, FACCa
a Third Department of Internal Medicine and the Cardiovascular Research Institute, Kurume University School of Medicine, Kurume, Japan
* Department of Pharmaceutics, Faculty of Pharmaceutical Science, Fukuoka University, Fukuoka, Japan
Division of Cardiology, Sugi Hospital, Ohmuta, Japan
Manuscript received November 10, 1997;
revised manuscript received April 2, 1998,
accepted April 22, 1998.
Address for correspondence: Dr. Hisashi Kai, Third Department of Internal Medicine and the Cardiovascular Research Institute, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan
kaihm{at}kurume.ktarn.or.jp
Objectives. This study was sought to investigate whether peripheral blood levels of matrix metalloproteases (MMPs) are affected in patients with acute coronary syndromes (ACS).
Background. Synthesis of MMPs has been reported in coronary atherosclerotic lesions in patients with unstable angina (UA), suggesting a pathogenic role of MMPs in the development of ACS.
Methods. Using sandwich enzyme immunoassay, serum MMP-2 and plasma MMP-9 were measured in 33 patients with ACS (22 with acute myocardial infarction [AMI], 11 with UA), 17 with stable effort angina (EA) and 17 normal control subjects.
Results. Serum MMP-2 in patients with UA and AMI on day 0 was two times greater than that in control subjects, and patients with EA showed higher MMP-2 levels than those in control subjects. Plasma MMP-9 in patients with UA and AMI on day 0 was elevated by threefold and twofold versus that in control subjects, respectively. In patients with UA and AMI who underwent medical treatment (n = 11 and 13, respectively), MMP-2 elevation was sustained until day 7. In patients with UA, MMP-9 elevation on day 0 was followed by a gradual decrease toward the control range up to day 7. Some patients with AMI showed a transient MMP-9 elevation with a peak on day 3, whereas in others, MMP-9 levels were significantly elevated on day 0 and remained higher than those in control subjects up to day 3.
Conclusions. Serial changes in serum MMP-2 and plasma MMP-9 were documented in patients with ACS. These findings provide an insight into the molecular mechanism of plaque destabilization.
|
Abbreviations and Acronyms
| | ACS | = acute coronary syndromes | | AMI | = acute myocardial infarction | | CK | = creatine kinase | | CRP | = C-reactive protein | | EA | = effort angina | | ECG | = electrocardiogram, electrocardiographic | | ECM | = extracellular matrix | | MMP | = matrix metalloprotease | | UA | = unstable angina | | VSMCs | = vascular smooth muscle cells |
|
This article has been cited by other articles:
|
|
|
|
 
M. Rajappa, S.K. Sen, and A. Sharma
Role of Pro-/Anti-Inflammatory Cytokines and Their Correlation With Established Risk Factors in South Indians With Coronary Artery Disease
Angiology,
August 1, 2009;
60(4):
419 - 426.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. K. Lund, J. Lucero, S. Lucas, M. C. Madden, J. D. McDonald, J.-C. Seagrave, T. L. Knuckles, and M. J. Campen
Vehicular Emissions Induce Vascular MMP-9 Expression and Activity Associated With Endothelin-1-Mediated Pathways
Arterioscler Thromb Vasc Biol,
April 1, 2009;
29(4):
511 - 517.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Garvin, L. Nilsson, J. Carstensen, L. Jonasson, and M. Kristenson
Plasma Levels of Matrix Metalloproteinase-9 are Independently Associated With Psychosocial Factors in a Middle-Aged Normal Population
Psychosom Med,
April 1, 2009;
71(3):
292 - 300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Fujimoto, D. Hartung, S. Ohshima, D. S. Edwards, J. Zhou, P. Yalamanchili, M. Azure, A. Fujimoto, S. Isobe, Y. Matsumoto, et al.
Molecular Imaging of Matrix Metalloproteinase in Atherosclerotic Lesions: Resolution With Dietary Modification and Statin Therapy
J. Am. Coll. Cardiol.,
December 2, 2008;
52(23):
1847 - 1857.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Welsh, P.H. Whincup, O. Papacosta, S.G. Wannamethee, L. Lennon, A. Thomson, A. Rumley, and G.D.O. Lowe
Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men
QJM,
October 1, 2008;
101(10):
785 - 791.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Adya, B. K. Tan, A. Punn, J. Chen, and H. S. Randeva
Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis
Cardiovasc Res,
May 1, 2008;
78(2):
356 - 365.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Diamanti-Kandarakis, S. Livadas, S. A Kandarakis, A. Margeli, and I. Papassotiriou
Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism?
Eur. J. Endocrinol.,
April 1, 2008;
158(4):
525 - 531.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. T. Yan, R. T. Yan, F. G. Spinale, R. Afzal, H. R. Gunasinghe, R. E. Stroud, R. S. McKelvie, and P. P. Liu
Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure
Eur J Heart Fail,
February 1, 2008;
10(2):
125 - 128.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Taurino, S. Raffa, M. Mastroddi, V. Visco, L. Rizzo, M. R. Torrisi, and V. Faraglia
Metalloproteinase Expression in Carotid Plaque and Its Correlation With Plasma Levels Before and After Carotid Endarterectomy
Vascular and Endovascular Surgery,
January 1, 2008;
41(6):
516 - 521.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. R. S. Packard and P. Libby
Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction
Clin. Chem.,
January 1, 2008;
54(1):
24 - 38.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. G. Spinale
Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function
Physiol Rev,
October 1, 2007;
87(4):
1285 - 1342.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Kelly, G. Cockerill, L. L. Ng, M. Thompson, S. Khan, N. J. Samani, and I. B. Squire
Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study
Eur. Heart J.,
March 5, 2007;
(2007)
ehm003v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Anwaruddin, A. T. Askari, and E. J. Topol
Redefining Risk in Acute Coronary Syndromes Using Molecular Medicine
J. Am. Coll. Cardiol.,
January 23, 2007;
49(3):
279 - 289.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hanefeld, N. Marx, A. Pfutzner, W. Baurecht, G. Lubben, E. Karagiannis, U. Stier, and T. Forst
Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein: The PIOSTAT Study
J. Am. Coll. Cardiol.,
January 23, 2007;
49(3):
290 - 297.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Koenig and N. Khuseyinova
Biomarkers of Atherosclerotic Plaque Instability and Rupture
Arterioscler Thromb Vasc Biol,
January 1, 2007;
27(1):
15 - 26.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Howard-Alpe, J. W. Sear, and P. Foex
Methods of detecting atherosclerosis in non-cardiac surgical patients; the role of biochemical markers
Br. J. Anaesth.,
December 1, 2006;
97(6):
758 - 769.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Abilleira, S. Bevan, and H. S Markus
The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis
J. Med. Genet.,
December 1, 2006;
43(12):
897 - 901.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. Paisley, C. J. O'Callaghan, K. C. Lewandowski, C. Parkinson, M. E. Roberts, W. M. Drake, J. P. Monson, P. J. Trainer, and H. S. Randeva
Reductions of Circulating Matrix Metalloproteinase 2 and Vascular Endothelial Growth Factor Levels after Treatment with Pegvisomant in Subjects with Acromegaly
J. Clin. Endocrinol. Metab.,
November 1, 2006;
91(11):
4635 - 4640.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Alfonso-Jaume, M. R. Bergman, R. Mahimkar, S. Cheng, Z. Q. Jin, J. S. Karliner, and D. H. Lovett
Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB
Am J Physiol Heart Circ Physiol,
October 1, 2006;
291(4):
H1838 - H1846.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Ernens, D. Rouy, E. Velot, Y. Devaux, and D. R. Wagner
Adenosine Inhibits Matrix Metalloproteinase-9 Secretion By Neutrophils: Implication of A2a Receptor and cAMP/PKA/Ca2+ Pathway
Circ. Res.,
September 15, 2006;
99(6):
590 - 597.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Webb, D. D. Bonnema, S. H. Ahmed, A. H. Leonardi, C. D. McClure, L. L. Clark, R. E. Stroud, W. C. Corn, L. Finklea, M. R. Zile, et al.
Specific Temporal Profile of Matrix Metalloproteinase Release Occurs in Patients After Myocardial Infarction: Relation to Left Ventricular Remodeling
Circulation,
September 5, 2006;
114(10):
1020 - 1027.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C. Lewandowski, J. Komorowski, D. P. Mikhalidis, M. Bienkiewicz, B. K. Tan, C. J. O'Callaghan, A. Lewinski, G. Prelevic, and H. S. Randeva
Effects of Hormone Replacement Therapy Type and Route of Administration on Plasma Matrix Metalloproteinases and Their Tissue Inhibitors in Postmenopausal Women
J. Clin. Endocrinol. Metab.,
August 1, 2006;
91(8):
3123 - 3130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Nilsson, L. Jonasson, J. Nijm, A. Hamsten, and P. Eriksson
Increased Plasma Concentration of Matrix Metalloproteinase-7 in Patients with Coronary Artery Disease
Clin. Chem.,
August 1, 2006;
52(8):
1522 - 1527.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-o Deguchi, M. Aikawa, C.-H. Tung, E. Aikawa, D.-E. Kim, V. Ntziachristos, R. Weissleder, and P. Libby
Inflammation in Atherosclerosis: Visualizing Matrix Metalloproteinase Action in Macrophages In Vivo
Circulation,
July 4, 2006;
114(1):
55 - 62.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. B. Holven, B. Halvorsen, V. Bjerkeli, J. K. Damas, K. Retterstol, L. Morkrid, L. Ose, P. Aukrust, and M. S. Nenseter
Impaired Inhibitory Effect of Interleukin-10 on the Balance Between Matrix Metalloproteinase-9 and Its Inhibitor in Mononuclear Cells From Hyperhomocysteinemic Subjects
Stroke,
July 1, 2006;
37(7):
1731 - 1736.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Armstrong, D. A. Morrow, and M. S. Sabatine
Inflammatory Biomarkers in Acute Coronary Syndromes: Part IV: Matrix Metalloproteinases and Biomarkers of Platelet Activation
Circulation,
March 7, 2006;
113(9):
e382 - e385.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C. Lewandowski, J. Komorowski, C. J. O'Callaghan, B. K. Tan, J. Chen, G. M. Prelevic, and H. S. Randeva
Increased Circulating Levels of Matrix Metalloproteinase-2 and -9 in Women with the Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab.,
March 1, 2006;
91(3):
1173 - 1177.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Schmidt, A. Bultmann, M. Ungerer, N. Joghetaei, O. Bulbul, S. Thieme, T. Chavakis, B. P. Toole, M. Gawaz, A. Schomig, et al.
Extracellular Matrix Metalloproteinase Inducer Regulates Matrix Metalloproteinase Activity in Cardiovascular Cells: Implications in Acute Myocardial Infarction
Circulation,
February 14, 2006;
113(6):
834 - 841.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. de Nooijer, C.J.N. Verkleij, J.H. von der Thusen, J.W. Jukema, E.E. van der Wall, Th. J.C. van Berkel, A.H. Baker, and E.A.L. Biessen
Lesional Overexpression of Matrix Metalloproteinase-9 Promotes Intraplaque Hemorrhage in Advanced Lesions But Not at Earlier Stages of Atherogenesis
Arterioscler Thromb Vasc Biol,
February 1, 2006;
26(2):
340 - 346.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Agewall
Matrix metalloproteinases and cardiovascular disease
Eur. Heart J.,
January 2, 2006;
27(2):
121 - 122.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Su, F. G. Spinale, L. W. Dobrucki, J. Song, J. Hua, S. Sweterlitsch, D. P. Dione, P. Cavaliere, C. Chow, B. N. Bourke, et al.
Noninvasive Targeted Imaging of Matrix Metalloproteinase Activation in a Murine Model of Postinfarction Remodeling
Circulation,
November 15, 2005;
112(20):
3157 - 3167.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Hirano-Ohmori, R. Takahashi, Y. Momiyama, H. Taniguchi, A. Yonemura, S. Tamai, K. Umegaki, H. Nakamura, K. Kondo, and F. Ohsuzu
Green Tea Consumption and Serum Malondialdehyde-Modified LDL Concentrations in Healthy Subjects
J. Am. Coll. Nutr.,
October 1, 2005;
24(5):
342 - 346.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Narula, A. V. Finn, and A. N. DeMaria
Picking Plaques That Pop ...
J. Am. Coll. Cardiol.,
June 21, 2005;
45(12):
1970 - 1973.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Garcia-Touchard, T. D. Henry, G. Sangiorgi, L. G. Spagnoli, A. Mauriello, C. Conover, and R. S. Schwartz
Extracellular Proteases in Atherosclerosis and Restenosis
Arterioscler Thromb Vasc Biol,
June 1, 2005;
25(6):
1119 - 1127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Stawowy, H. Meyborg, D. Stibenz, N. B. P. Stawowy, M. Roser, U. Thanabalasingam, J. P. Veinot, M. Chretien, N. G. Seidah, E. Fleck, et al.
Furin-Like Proprotein Convertases Are Central Regulators of the Membrane Type Matrix Metalloproteinase-Pro-Matrix Metalloproteinase-2 Proteolytic Cascade in Atherosclerosis
Circulation,
May 31, 2005;
111(21):
2820 - 2827.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. S. Apple, A. H.B. Wu, J. Mair, J. Ravkilde, M. Panteghini, J. Tate, F. Pagani, R. H. Christenson, M. Mockel, O. Danne, et al.
Future Biomarkers for Detection of Ischemia and Risk Stratification in Acute Coronary Syndrome
Clin. Chem.,
May 1, 2005;
51(5):
810 - 824.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K de Leeuw, J-S Sanders, C Stegeman, A Smit, C G Kallenberg, and M Bijl
Accelerated atherosclerosis in patients with Wegener's granulomatosis
Ann Rheum Dis,
May 1, 2005;
64(5):
753 - 759.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. T. Wu and L. L. Wu
Association of Soluble Markers with Various Stages and Major Events of Atherosclerosis
Ann. Clin. Lab. Sci.,
January 1, 2005;
35(3):
240 - 250.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Tazaki, K. Minoguchi, T. Yokoe, K. T. R. Samson, H. Minoguchi, A. Tanaka, Y. Watanabe, and M. Adachi
Increased Levels and Activity of Matrix Metalloproteinase-9 in Obstructive Sleep Apnea Syndrome
Am. J. Respir. Crit. Care Med.,
December 15, 2004;
170(12):
1354 - 1359.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Abbott, Y. Huang, D. Liu, R. Hickey, D. S. Krause, and F. J. Giordano
Stromal Cell-Derived Factor-1{alpha} Plays a Critical Role in Stem Cell Recruitment to the Heart After Myocardial Infarction but Is Not Sufficient to Induce Homing in the Absence of Injury
Circulation,
November 23, 2004;
110(21):
3300 - 3305.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Zouridakis, P. Avanzas, R. Arroyo-Espliguero, S. Fredericks, and J. C. Kaski
Markers of Inflammation and Rapid Coronary Artery Disease Progression in Patients With Stable Angina Pectoris
Circulation,
September 28, 2004;
110(13):
1747 - 1753.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Ohta, T. Nakajima, A. Y. L. Cheah, S. H. E. Zaidi, N. Kaviani, F. Dawood, X.-M. You, P. Liu, M. Husain, and M. Rabinovitch
Elafin-overexpressing mice have improved cardiac function after myocardial infarction
Am J Physiol Heart Circ Physiol,
July 1, 2004;
287(1):
H286 - H292.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. S. Randeva, K. C. Lewandowski, J. Komorowski, R. D. Murray, C. J. O'Callaghan, E. W. Hillhouse, H. Stepien, and S. M. Shalet
Growth Hormone Replacement Decreases Plasma Levels of Matrix Metalloproteinases (2 and 9) and Vascular Endothelial Growth Factor in Growth Hormone-Deficient Individuals
Circulation,
May 25, 2004;
109(20):
2405 - 2410.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Xu, S. Zhao, H. Zhou, H. Ye, and J. Li
Atorvastatin Lowers Plasma Matrix Metalloproteinase-9 in Patients with Acute Coronary Syndrome
Clin. Chem.,
April 1, 2004;
50(4):
750 - 753.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. A. Arenas, Y. Xu, P. Lopez-Jaramillo, and S. T. Davidge
Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-{alpha}
Am J Physiol Cell Physiol,
April 1, 2004;
286(4):
C779 - C784.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Luttun, E. Lutgens, A. Manderveld, K. Maris, D. Collen, P. Carmeliet, and L. Moons
Loss of Matrix Metalloproteinase-9 or Matrix Metalloproteinase-12 Protects Apolipoprotein E-Deficient Mice Against Atherosclerotic Media Destruction but Differentially Affects Plaque Growth
Circulation,
March 23, 2004;
109(11):
1408 - 1414.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Yamazaki, J.-D. Lee, H. Shimizu, H. Uzui, and T. Ueda
Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure
Eur J Heart Fail,
January 1, 2004;
6(1):
41 - 45.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Chapman and F. G. Spinale
Extracellular protease activation and unraveling of the myocardial interstitium: critical steps toward clinical applications
Am J Physiol Heart Circ Physiol,
January 1, 2004;
286(1):
H1 - H10.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Potier, M. Karl, S. J. Elliot, G. E. Striker, and L. J. Striker
Response to sex hormones differs in atherosclerosis-susceptible and -resistant mice
Am J Physiol Endocrinol Metab,
December 1, 2003;
285(6):
E1237 - E1245.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. B Jones, D. C Sane, and D. M Herrington
Matrix metalloproteinases: A review of their structure and role in acute coronary syndrome
Cardiovasc Res,
October 1, 2003;
59(4):
812 - 823.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Nagata, H. Kai, R. Shibata, M. Koga, A. Yoshimura, and T. Imaizumi
Oncostatin M, an Interleukin-6 Family Cytokine, Upregulates Matrix Metalloproteinase-9 Through the Mitogen-Activated Protein Kinase Kinase-Extracellular Signal-Regulated Kinase Pathway in Cultured Smooth Muscle Cells
Arterioscler Thromb Vasc Biol,
April 1, 2003;
23(4):
588 - 593.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Blankenberg, H. J. Rupprecht, O. Poirier, C. Bickel, M. Smieja, G. Hafner, J. Meyer, F. Cambien, L. Tiret, and for the AtheroGene Investigators
Plasma Concentrations and Genetic Variation of Matrix Metalloproteinase 9 and Prognosis of Patients With Cardiovascular Disease
Circulation,
April 1, 2003;
107(12):
1579 - 1585.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Marx, J. Froehlich, L. Siam, J. Ittner, G. Wierse, A. Schmidt, H. Scharnagl, V. Hombach, and W. Koenig
Antidiabetic PPAR{gamma}-Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Patients With Coronary Artery Disease
Arterioscler Thromb Vasc Biol,
February 1, 2003;
23(2):
283 - 288.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. S. Bradham Jr, H. Gunasinghe, J. R. Holder, M. Multani, D. Killip, M. Anderson, D. Meyer, W. H. Spencer III, G. Torre-Amione, and F. G. Spinale
Release of matrix metalloproteinases following alcohol septal ablation in hypertrophic obstructive cardiomyopathy
J. Am. Coll. Cardiol.,
December 18, 2002;
40(12):
2165 - 2173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Uzui, A. Harpf, M. Liu, T. M. Doherty, A. Shukla, N.-N. Chai, P. V. Tripathi, S. Jovinge, D. J. Wilkin, K. Asotra, et al.
Increased Expression of Membrane Type 3-Matrix Metalloproteinase in Human Atherosclerotic Plaque: Role of Activated Macrophages and Inflammatory Cytokines
Circulation,
December 10, 2002;
106(24):
3024 - 3030.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P.M. Timms, N. Mannan, G.A. Hitman, K. Noonan, P.G. Mills, D. Syndercombe-court, E. Aganna, C.P. Price, and B.J. Boucher
Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders?
QJM,
December 1, 2002;
95(12):
787 - 796.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. K. Koh, J. W. Son, J. Y. Ahn, D. K. Jin, H. S. Kim, Y. M. Choi, D. S. Kim, E.-M. Jeong, G. S. Park, I. S. Choi, et al.
Comparative Effects of Diet and Statin on NO Bioactivity and Matrix Metalloproteinases in Hypercholesterolemic Patients With Coronary Artery Disease
Arterioscler Thromb Vasc Biol,
September 1, 2002;
22(9):
e19 - 23.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.S. Celermajer
Understanding the pathophysiology of the arterial wall: which method should we choose?
Eur. Heart J. Suppl.,
September 1, 2002;
4(suppl_F):
F24 - F28.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. M. Haffner, A. S. Greenberg, W. M. Weston, H. Chen, K. Williams, and M. I. Freed
Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus
Circulation,
August 6, 2002;
106(6):
679 - 684.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Thompson and I. B. Squire
Matrix metalloproteinase-9 expression after myocardial infarction: physiological or pathological?
Cardiovasc Res,
June 1, 2002;
54(3):
495 - 498.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Romanic, S. M. Harrison, W. Bao, C. L. Burns-Kurtis, S. Pickering, J. Gu, E. Grau, J. Mao, G. M. Sathe, E. H. Ohlstein, et al.
Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9
Cardiovasc Res,
June 1, 2002;
54(3):
549 - 558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Loftus and M. Thompson
The role of matrix metalloproteinases in vascular disease
Vascular Medicine,
May 1, 2002;
7(2):
117 - 133.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. G. Spinale
Matrix Metalloproteinases: Regulation and Dysregulation in the Failing Heart
Circ. Res.,
March 22, 2002;
90(5):
520 - 530.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. S. Galis and J. J. Khatri
Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: The Good, the Bad, and the Ugly
Circ. Res.,
February 22, 2002;
90(3):
251 - 262.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. E.J.M. Creemers, J. P.M. Cleutjens, J. F.M. Smits, and M. J.A.P. Daemen
Matrix Metalloproteinase Inhibition After Myocardial Infarction: A New Approach to Prevent Heart Failure?
Circ. Res.,
August 3, 2001;
89(3):
201 - 210.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Montaner, J. Alvarez-Sabin, C. Molina, A. Angles, S. Abilleira, J. Arenillas, M. A. Gonzalez, and J. Monasterio
Matrix Metalloproteinase Expression After Human Cardioembolic Stroke: Temporal Profile and Relation to Neurological Impairment
Stroke,
August 1, 2001;
32(8):
1759 - 1766.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Joffs, H. R. Gunasinghe, M. M. Multani, B. H. Dorman, J. M. Kratz, A. J. Crumbley III, F. A. Crawford Jr, and F. G. Spinale
Cardiopulmonary bypass induces the synthesis and release of matrix metalloproteinases
Ann. Thorac. Surg.,
May 1, 2001;
71(5):
1518 - 1523.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.R Azar, S Rinfret, P Theroux, P.H Stone, R Dakshinamurthy, Y.-J Feng, A.H.B Wu, G Range, and D.D Waters
A randomized placebo-controlled trial to assess the efficacy of antiinflammatory therapy with methylprednisolone in unstable angina (MUNA trial)
Eur. Heart J.,
December 2, 2000;
21(24):
2026 - 2032.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Zanger, B. K. Yang, J. Ardans, M. A. Waclawiw, G. Csako, L. M. Wahl, and R. O. Cannon III
Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management
J. Am. Coll. Cardiol.,
November 15, 2000;
36(6):
1797 - 1802.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Lu, Z. Gunja-Smith, J. F. Woessner, P. C. Ursell, T. Nissen, R. E. Galardy, Y. Xu, P. Zhu, and G. G. Schwartz
Matrix metalloproteinases and collagen ultrastructure in moderate myocardial ischemia and reperfusion in vivo
Am J Physiol Heart Circ Physiol,
August 1, 2000;
279(2):
H601 - H609.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. M. Loftus, A. R. Naylor, S. Goodall, M. Crowther, L. Jones, P. R. F. Bell, and M. M. Thompson
Increased Matrix Metalloproteinase-9 Activity in Unstable Carotid Plaques : A Potential Role in Acute Plaque Disruption
Stroke,
January 1, 2000;
31(1):
40 - 47.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Uemura, H. Matsushita, W. Li, A. J. Glassford, T. Asagami, K.-H. Lee, D. G. Harrison, and P. S. Tsao
Diabetes Mellitus Enhances Vascular Matrix Metalloproteinase Activity : Role of Oxidative Stress
Circ. Res.,
June 22, 2001;
88(12):
1291 - 1298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
